Point-of-Care (POC) Immunoassay Devices Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export 

Introduction to the Point-of-Care (POC) Immunoassay Devices Market 

Point-of-Care (POC) Immunoassay Devices market size is estimated to be $12500 Million in 2025. The market was $11792 Million in 2024 and will reach $18795 Million by 2032.
The Point-of-Care (POC) Immunoassay Devices Market is rapidly transforming the healthcare landscape by enabling quick and reliable diagnostic tests outside traditional laboratory settings. This shift is driven by the increasing demand for real-time medical insights, particularly in emergency, rural, and remote settings. Over the years, the market for POC immunoassay devices has seen significant growth, driven by advancements in diagnostic technologies and an increasing focus on patient-centric care. As more healthcare providers prioritize accessible, cost-effective solutions, the POC immunoassay devices market continues to evolve, with applications extending across various medical fields, including infectious diseases, cardiology, oncology, and diabetes management. 

Growth Drivers of the Point-of-Care (POC) Immunoassay Devices Market 

Growing Demand for Rapid Diagnostics 

One of the primary factors propelling the growth of the Point-of-Care (POC) Immunoassay Devices Market is the increasing demand for rapid diagnostic solutions. As patients and healthcare providers alike seek faster results, the need for quick turnaround times for test results is evident. For example, in the context of infectious disease outbreaks, such as the COVID-19 pandemic, the demand for POC immunoassay devices soared, with many companies scaling production to meet this heightened need. This trend is expected to continue, with market analysts projecting a compound annual growth rate (CAGR) of over 7% for the next five years. 

Additionally, the rise of chronic conditions like diabetes and cardiovascular diseases has heightened the demand for continuous monitoring. As more individuals require frequent testing, POC immunoassay devices, which allow users to test blood glucose, cholesterol, and other biomarkers at home, offer a convenient and effective solution. With over 400 million people globally living with diabetes, this segment of the market is likely to see exponential growth in the coming years. 

Increasing Healthcare Investments in Developing Regions 

Emerging markets, particularly in Asia-Pacific and Latin America, are becoming crucial players in the Point-of-Care (POC) Immunoassay Devices Market. Countries such as India, China, and Brazil are making significant investments in healthcare infrastructure, driving the demand for affordable diagnostic tools. For instance, in India, the government’s push toward expanding healthcare access in rural areas is creating a favorable environment for POC devices, which are more easily deployed in remote locations compared to traditional lab-based diagnostics. 

In Latin America, where healthcare access remains inconsistent, POC immunoassay devices are helping bridge the gap by providing affordable and accessible testing options. This trend has been further accelerated by government incentives and initiatives aimed at expanding diagnostic capabilities in underserved regions. These regions represent untapped growth opportunities, making them key focus areas for companies involved in the POC immunoassay device market. 

Technological Advancements in Point-of-Care (POC) Immunoassay Devices 

The integration of cutting-edge technologies such as microfluidics, biosensors, and nanotechnology has revolutionized the capabilities of POC immunoassay devices. Innovations in these technologies are not only enhancing the accuracy and sensitivity of diagnostic tests but are also making them more compact and user-friendly. These advancements have significantly improved the performance of immunoassay devices, allowing for a broader range of testing options with quicker turnaround times. 

For example, the introduction of portable, easy-to-use immunoassay devices that utilize smartphone technology for data transmission and result interpretation has brought a new level of convenience to users. This technology not only makes testing faster but also enables real-time data sharing with healthcare professionals, improving patient outcomes. As these devices become more accessible and affordable, the market for POC immunoassay devices is set for continued expansion. 

Increasing Prevalence of Chronic Diseases and Their Impact on the Market 

Growing Incidence of Chronic Diseases 

The Point-of-Care (POC) Immunoassay Devices Market is being significantly shaped by the rising prevalence of chronic diseases globally. As chronic conditions such as diabetes, hypertension, and cardiovascular diseases continue to escalate, the demand for continuous monitoring and quick diagnostic solutions has intensified. In fact, the World Health Organization (WHO) estimates that chronic diseases will account for over 70% of all deaths globally by 2030. 

The increasing burden of these diseases is pushing healthcare providers to adopt solutions that allow for frequent monitoring of patients, which is precisely what POC immunoassay devices offer. Devices for monitoring blood glucose, lipid levels, and other biomarkers are becoming essential in managing these chronic conditions. The global diabetes market alone is projected to reach $94 billion by 2028, with POC devices accounting for a significant share of this growth. 

Improving Management of Infectious Diseases 

Another major driver for the POC immunoassay devices market is the growing need for rapid detection of infectious diseases. The COVID-19 pandemic underscored the importance of rapid diagnostics in controlling the spread of infections. In response, there was a surge in demand for POC immunoassay devices capable of providing quick results, including antigen tests for COVID-19 and other infectious diseases like HIV, influenza, and malaria. 

As global health systems become more focused on preparedness and rapid response, the need for POC immunoassay devices continues to rise. In regions where healthcare resources are limited, these devices offer a cost-effective solution to ensure timely diagnosis and treatment. Furthermore, the continued development of multiplex testing—where multiple pathogens can be detected in a single test—further enhances the market’s growth potential, offering healthcare providers greater efficiency in their diagnostic capabilities. 

The Role of Regulatory Changes in Shaping the Point-of-Care (POC) Immunoassay Devices Market 

Expanding Regulatory Approvals and Market Access 

The regulatory landscape plays a pivotal role in shaping the future of the Point-of-Care (POC) Immunoassay Devices Market. The adoption of more flexible regulatory pathways for the approval of diagnostic devices is facilitating faster market access, especially for innovative products. For example, the U.S. Food and Drug Administration (FDA) has streamlined the approval process for certain POC immunoassay devices, enabling faster deployment in clinical settings and for consumer use. 

Furthermore, in markets such as Europe, the implementation of the In Vitro Diagnostic Regulation (IVDR) has opened up new opportunities for manufacturers, as the regulation supports the introduction of new technologies and innovations in the diagnostics space. As more regions adopt supportive regulatory frameworks, the market will continue to see a rise in the number of products approved for use, driving further expansion of the POC immunoassay devices market. 

Consumer-Driven Health Initiatives and Their Impact 

The increasing demand for consumer-driven health management is another key driver of the Point-of-Care (POC) Immunoassay Devices Market. As healthcare consumers become more proactive in managing their health, they are seeking solutions that allow them to monitor their conditions without the need for frequent doctor visits. This shift toward at-home diagnostics has led to a rise in the adoption of POC immunoassay devices for a variety of health conditions. 

For example, wearable devices that monitor vital signs and track chronic conditions like hypertension and diabetes are gaining traction among consumers. These consumer-driven health initiatives are contributing to the widespread acceptance of POC immunoassay devices, creating new market segments and spurring demand for easy-to-use, accurate diagnostic tools. 

“Track Country-wise Point-of-Care (POC) Immunoassay Devices Production and Demand through our Database”

• • • Point-of-Care (POC) Immunoassay Devices sales volume database for 27+ countries worldwide

North America: Dominating the Point-of-Care (POC) Immunoassay Devices Market 

North America continues to lead the global Point-of-Care (POC) Immunoassay Devices Market, driven by the region’s robust healthcare infrastructure, high adoption of advanced technologies, and the presence of key market players. The United States, in particular, remains the largest consumer of POC immunoassay devices, accounting for a significant share of the market. The demand for these devices is fueled by several factors, including a high prevalence of chronic diseases, such as diabetes and cardiovascular conditions, and the increasing need for rapid diagnostic tools. 

For instance, the United States’ diabetes prevalence is estimated to be around 10.5% of the population, translating to an enormous demand for POC immunoassay devices that enable frequent monitoring of blood glucose levels. Furthermore, the FDA’s fast-track approval process for innovative diagnostic technologies has spurred the introduction of new POC immunoassay devices to the market. North America’s focus on personalized healthcare, home diagnostics, and accessible patient care ensures that the demand for POC immunoassay devices will remain high. 

Europe: Rising Adoption and Regulatory Support for Point-of-Care (POC) Immunoassay Devices 

Europe is experiencing steady growth in the Point-of-Care (POC) Immunoassay Devices Market, driven by an aging population, increased healthcare expenditures, and a growing emphasis on early diagnosis and prevention. Countries like Germany, France, the United Kingdom, and Italy are seeing significant demand for POC immunoassay devices due to an increased focus on patient-centric care and timely medical interventions. The European market is also benefiting from the supportive regulatory environment, such as the In Vitro Diagnostic Regulation (IVDR), which enables faster market access for new products. 

For example, Germany’s robust healthcare system and the government’s focus on digital health initiatives have fostered the adoption of POC immunoassay devices. In the UK, the NHS has been incorporating these devices into routine testing procedures to improve diagnostics for diseases like HIV and hepatitis. This trend is also supported by the rise in personalized medicine, where diagnostic tools play a critical role in providing tailored treatments for patients. As the demand for these devices in Europe rises, market players are increasingly focusing on local manufacturing and distribution channels to cater to this growing demand. 

Asia-Pacific: A Lucrative Opportunity in the Point-of-Care (POC) Immunoassay Devices Market 

The Asia-Pacific region represents one of the fastest-growing markets for Point-of-Care (POC) Immunoassay Devices, driven by rapid urbanization, rising disposable incomes, and improvements in healthcare infrastructure. Countries like China and India are emerging as key contributors to the market, fueled by government initiatives aimed at improving healthcare access in rural and remote areas. The demand for POC immunoassay devices in this region is also spurred by the high prevalence of infectious diseases, such as tuberculosis and hepatitis, and the need for rapid diagnostics. 

For instance, India’s healthcare system has seen significant upgrades in recent years, with the government increasing investment in healthcare infrastructure and extending services to underserved areas. POC devices, which can be deployed easily in remote locations, are gaining popularity due to their ability to provide quick results in the absence of centralized diagnostic laboratories. Similarly, in China, the rapid rise of chronic diseases, including diabetes and cardiovascular issues, has boosted the demand for POC immunoassay devices that offer continuous and immediate testing solutions. 

Latin America and the Middle East: Emerging Markets for Point-of-Care (POC) Immunoassay Devices 

Latin America and the Middle East are emerging as high-potential markets for Point-of-Care (POC) Immunoassay Devices. In these regions, the increasing demand for affordable, efficient diagnostic solutions is being driven by growing healthcare access and the rising burden of chronic and infectious diseases. Countries like Brazil, Mexico, and the UAE are seeing increased adoption of POC devices, as they offer a practical solution for regions with limited access to advanced medical testing facilities. 

For example, Brazil’s healthcare system has been undergoing reform with an emphasis on improving access to healthcare in rural areas, leading to greater demand for POC immunoassay devices. The Middle East, particularly in the UAE and Saudi Arabia, is investing heavily in advanced healthcare technologies, and POC devices are becoming integral to the healthcare system due to their efficiency and cost-effectiveness. As healthcare infrastructure in these regions continues to expand, the market for POC immunoassay devices will continue to grow rapidly. 

Point-of-Care (POC) Immunoassay Devices Manufacturing: A Growing Industry 

Technological Advancements in Point-of-Care (POC) Immunoassay Devices Manufacturing 

The manufacturing of Point-of-Care (POC) Immunoassay Devices has evolved significantly in recent years, driven by technological advancements in miniaturization, biosensing, and microfluidics. Manufacturers are investing heavily in R&D to develop smaller, more efficient, and more accurate devices. The integration of digital technologies, such as smartphone apps and cloud connectivity, has further enhanced the functionality and user-friendliness of these devices. 

For instance, devices that once required complex lab infrastructure can now be used by patients in the comfort of their homes, providing real-time diagnostic results. Additionally, the miniaturization of these devices has made them portable, allowing healthcare providers to conduct on-the-spot testing in various settings, including emergency rooms, outpatient clinics, and even in the home. As consumer demand for home diagnostics increases, the need for efficient and scalable manufacturing processes becomes critical. Manufacturers are also exploring the use of disposable, low-cost materials to lower production costs and make these devices accessible to a larger global population. 

Increasing Focus on Sustainability in Point-of-Care (POC) Immunoassay Devices Manufacturing 

Sustainability has become a key focus for manufacturers in the Point-of-Care (POC) Immunoassay Devices Market. With environmental concerns on the rise, companies are increasingly adopting sustainable manufacturing practices. For instance, the use of recyclable materials and energy-efficient production processes is gaining traction within the industry. The shift toward sustainable manufacturing is not only driven by environmental considerations but also by consumer demand for eco-friendly products. 

As part of this trend, manufacturers are focusing on reducing waste and improving the lifecycle management of POC devices. By implementing more sustainable practices, manufacturers can reduce production costs, align with global environmental goals, and meet regulatory standards for green products. This shift is likely to play a significant role in driving long-term growth in the POC immunoassay devices market, as eco-conscious consumers and healthcare providers demand greener, more sustainable products. 

Market Segmentation in the Point-of-Care (POC) Immunoassay Devices Market 

Based on Product Type: Expanding Range of Diagnostic Solutions 

The Point-of-Care (POC) Immunoassay Devices Market is segmented based on product type, including immunoassay analyzers, immunoassay test kits, and consumables. Immunoassay analyzers are expected to hold a dominant share of the market, as these devices provide comprehensive testing capabilities and are used in hospitals, clinics, and other healthcare facilities. The rising demand for portable analyzers is also driving market growth, as these devices offer on-the-spot results for a variety of conditions. 

On the other hand, immunoassay test kits are witnessing growing demand due to their ease of use and affordability. For example, pregnancy tests, HIV tests, and cholesterol tests are becoming increasingly popular in home diagnostics, driving the segment’s growth. The consumables segment, which includes reagents and diagnostic kits, also plays a significant role in the market, as regular use of consumables is required for ongoing diagnostic testing. 

Based on Application: Key Healthcare Segments 

The Point-of-Care (POC) Immunoassay Devices Market is also segmented by application, which includes infectious diseases, oncology, cardiology, diabetes, and others. The infectious diseases segment is expected to dominate the market due to the increasing demand for rapid diagnostic tools to detect diseases like COVID-19, HIV, and influenza. The ability to conduct immediate tests for infectious diseases at the point of care has proven invaluable, particularly in emergency and rural healthcare settings. 

Oncology and cardiology are emerging as key application areas as well. The rise in the global incidence of cancer and cardiovascular diseases has spurred the demand for POC devices that can offer early detection and continuous monitoring of biomarkers. The diabetes segment is also poised for substantial growth, as POC immunoassay devices enable diabetic patients to test blood glucose levels regularly, improving disease management and reducing complications. 

Price Trends in the Point-of-Care (POC) Immunoassay Devices Market 

The Impact of Technological Advancements on Pricing Strategies 

The pricing trends in the Point-of-Care (POC) Immunoassay Devices Market are heavily influenced by technological advancements and the growing demand for more affordable healthcare solutions. While the initial price of these devices may be relatively high, continuous improvements in manufacturing efficiency and economies of scale are expected to drive down costs over time. For instance, as the use of microfluidics and sensor technology becomes more widespread, manufacturers are able to produce devices at lower costs without compromising on performance. 

Affordable Point-of-Care (POC) Immunoassay Devices for Emerging Markets 

In emerging markets, pricing remains a critical factor in the adoption of POC immunoassay devices. Manufacturers are focusing on producing low-cost, high-performance devices that can meet the needs of resource-constrained healthcare settings. In regions like Africa, Southeast Asia, and parts of Latin America, affordable POC immunoassay devices are essential for improving healthcare access and diagnostic capabilities. The demand for low-cost devices is likely to drive innovation in pricing models, making POC devices more accessible to a broader range of consumers. 

“Point-of-Care (POC) Immunoassay Devices Manufacturing Database”

• • • Point-of-Care (POC) Immunoassay Devices top manufacturers market share for 27+ manufacturers
    • Top 7 manufacturers and top 17 manufacturers of Point-of-Care (POC) Immunoassay Devices in North America, Europe, Asia Pacific
    • Point-of-Care (POC) Immunoassay Devices sales dashboard, Point-of-Care (POC) Immunoassay Devices sales data in excel format

Leading Manufacturers in the Point-of-Care (POC) Immunoassay Devices Market 

The Point-of-Care (POC) Immunoassay Devices Market is a highly competitive sector, featuring several prominent manufacturers driving innovation and accessibility in diagnostic solutions. These companies are leveraging cutting-edge technologies to develop devices that deliver fast, accurate, and reliable results, making diagnostic testing more efficient across a variety of healthcare settings. 

Abbott Laboratories 

Abbott Laboratories is a dominant force in the POC immunoassay devices market. The company’s product lines, such as the Alinity™ and ARCHITECT™ platforms, are designed to deliver high-throughput, accurate, and quick diagnostic results, particularly in immunoassay testing. Abbott’s i-STAT™ system is another key product, offering handheld, cartridge-based testing for emergency and critical care environments. This system provides rapid results for a wide range of tests, which is crucial in time-sensitive medical situations. The success of Abbott’s devices is largely attributed to their portability, ease of use, and integration with healthcare IT systems for real-time patient data sharing. 

Siemens Healthineers 

Siemens Healthineers has a significant presence in the POC immunoassay devices market, with its Atellica® and ADVIA® Centaur platforms offering advanced diagnostic solutions. These systems are highly regarded for their precision in testing and ability to perform a wide range of assays, including endocrinology, cardiology, and infectious disease testing. Siemens’ products also integrate automation and digitalization, which not only enhances diagnostic accuracy but also increases efficiency in clinical laboratories, reducing the time needed to provide results. The company’s focus on improving patient care through advanced diagnostic tools ensures its continued leadership in the market. 

F. Hoffmann-La Roche Ltd 

Roche Diagnostics, part of F. Hoffmann-La Roche Ltd, is another major player in the POC immunoassay devices market. Roche’s cobas® and Elecsys® platforms are renowned for their ability to perform high-sensitivity tests for a wide range of biomarkers, including those related to cardiac, oncology, and infectious diseases. These devices are used in both professional and home settings, offering fast results that help clinicians make more informed decisions. Roche’s consistent investment in R&D has helped solidify its position in the market, especially in the field of precision medicine, where accurate and reliable diagnostics are critical. 

Danaher Corporation 

Danaher Corporation, through its subsidiary Beckman Coulter, plays a pivotal role in the POC immunoassay devices market. Beckman Coulter’s Access® and DxI™ systems are known for their robust capabilities in handling a broad range of assays, from routine tests to more specialized applications. These systems are designed to deliver quick and accurate results, with a focus on improving laboratory efficiency and enabling clinicians to make quicker, more informed decisions. Danaher’s strong emphasis on improving healthcare processes and outcomes has helped it maintain a significant share of the market. 

Thermo Fisher Scientific Inc. 

Thermo Fisher Scientific Inc. is a global leader in scientific instruments and diagnostics, offering a variety of POC immunoassay devices, including the ImmunoCAP™ and Phadia™ platforms. These systems are predominantly used for allergy and autoimmune testing, providing fast and accurate results for conditions such as asthma, allergies, and autoimmune disorders. Thermo Fisher’s commitment to advancing healthcare technology and providing high-quality diagnostic tools has positioned it as a key player in the global market. 

bioMérieux 

bioMérieux is a major contributor to the POC immunoassay devices market, particularly in the field of infectious disease diagnostics. The company’s VIDAS® and BIOFIRE® systems are highly regarded for their ability to deliver rapid and accurate results for a variety of infectious diseases, including COVID-19, HIV, and tuberculosis. These systems are particularly valuable in settings where quick diagnosis is crucial for controlling outbreaks and improving patient outcomes. bioMérieux’s focus on innovation and addressing global health challenges ensures its continued leadership in the POC diagnostics space. 

QuidelOrtho Corporation 

QuidelOrtho Corporation specializes in rapid diagnostic testing, particularly in the areas of infectious diseases. Their Sofia® and QuickVue® platforms are designed for the detection of pathogens such as influenza, COVID-19, and respiratory syncytial virus (RSV), among others. These devices are popular in point-of-care settings because of their speed and accuracy, allowing for immediate clinical decisions. The company’s emphasis on fast, user-friendly diagnostic solutions has helped it carve out a niche in the POC immunoassay devices market. 

Sysmex Corporation 

Sysmex Corporation, a leader in hematology diagnostics, has also expanded its presence in the POC immunoassay devices market. The company’s diagnostic instruments and reagents, including POC immunoassay devices, are known for their high reliability and precision. Sysmex is committed to delivering diagnostic solutions that improve patient outcomes, particularly in areas where access to centralized laboratories is limited. As demand for efficient, rapid diagnostics continues to grow, Sysmex’s role in the POC space is set to increase. 

BD (Becton, Dickinson and Company) 

BD is a global leader in medical technology, including point-of-care diagnostic solutions. Their Veritor™ system is designed for the rapid detection of infectious diseases, including influenza and COVID-19. This system is particularly valued for its ability to provide quick, actionable results in clinical settings such as emergency rooms, urgent care centers, and physician offices. BD’s focus on developing innovative, easy-to-use diagnostic tools continues to position it as a key player in the POC immunoassay devices market. 

DiaSorin S.p.A. 

DiaSorin S.p.A., an Italian company specializing in diagnostic solutions, also plays a prominent role in the POC immunoassay devices market. Its Liaison® platform offers a broad menu of assays, which can detect a variety of diseases and conditions, from infections to chronic diseases. The platform’s versatility and high performance make it a valuable tool in point-of-care settings. DiaSorin’s commitment to improving diagnostic accuracy and speed ensures its continued relevance in the competitive POC market. 

Market Share Distribution Among Manufacturers 

The global Point-of-Care (POC) Immunoassay Devices Market is fragmented, with several key players holding substantial market shares. Roche Diagnostics and Abbott Laboratories are the two dominant players, accounting for a significant portion of the market. Roche’s robust portfolio, including the Elecsys® and cobas® platforms, positions it as the leader, with approximately 20% of the market share. Abbott Laboratories follows closely, with a market share of around 18%, bolstered by its i-STAT™ and Alinity™ product lines, which are widely used in a range of healthcare settings. 

Siemens Healthineers and Thermo Fisher Scientific are also major players, each holding significant shares in the market. Siemens, with its Atellica® and ADVIA® systems, commands roughly 12% of the market, while Thermo Fisher’s ImmunoCAP™ and Phadia™ systems contribute to its share of around 10%. Other players, including bioMérieux, Danaher Corporation, QuidelOrtho, and Sysmex, hold smaller portions of the market but are critical in driving innovation and catering to specialized diagnostic needs. 

Recent Developments and Industry News 

In recent years, manufacturers in the POC immunoassay devices market have made significant strides in product development and market expansion. 

• January 2025: Anbio Biotechnology launched its Dry CLIA Solution ADL-1000, a new device designed to provide fast, cost-effective diagnostic results. This system is particularly aimed at improving diagnostic efficiency in clinical settings that require high-performance testing with minimal time and effort. 

• April 2024: Abbott Laboratories received FDA clearance for its i-STAT TBI cartridge for use with whole blood samples, expanding its portfolio in the emergency care space. This development highlights Abbott’s commitment to providing accurate, real-time diagnostic solutions for critical conditions. 

• January 2022: Roche launched its cobas pulse system in select CE Mark countries, a connected point-of-care solution designed for professional blood glucose monitoring. This product expands Roche’s footprint in the diabetes management market. 

“Point-of-Care (POC) Immunoassay Devices Production Data and Point-of-Care (POC) Immunoassay Devices Production Trend”

• • • Point-of-Care (POC) Immunoassay Devices sales database for historical years, 10 years historical data
    • Point-of-Care (POC) Immunoassay Devices sales data and forecast for next 7 years